| Feasibility of a Carbohydrate-restricted, High-fat Diet on Head and Neck Squamous Cell Carcinoma Outcomes (NCT04253808) | University of Illinois at Urbana-Champaign | 2020-02-03 |
| Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer? (NCT05217212) | Luzerner Kantonsspital | 2020-01-01 |
| SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (NCT04146402) | Sinocelltech Ltd. | 2019-12-31 |
| Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma (NCT04093115) | Beijing Konruns Pharmaceutical Co., Ltd. | 2019-12-09 |
| Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients (NCT04164238) | First Affiliated Hospital of Zhejiang University | 2019-11-07 |
| Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy (NCT02990936) | Centre Hospitalier Universitaire UCLouvain Namur | 2019-11-01 |
| Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma (NCT04146181) | Sinocelltech Ltd. | 2019-10-31 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT04032704) | Seagen Inc. | 2019-10-09 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors (NCT04045496) | Jacobio Pharmaceuticals Co., Ltd. | 2019-09-26 |
| Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (NCT04096638) | invoX Pharma Limited | 2019-09-23 |
| Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer (NCT04110249) | Roswell Park Cancer Institute | 2019-09-06 |
| A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer (NCT03735680) | OncoNano Medicine, Inc. | 2019-08-09 |
| Liquid Biopsy in Head and Neck Cancer (NCT03926468) | Turku University Hospital | 2019-08-01 |
| Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer (NCT03405142) | Eben Rosenthal | 2019-08-01 |
| INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy (NCT03953976) | University of Texas Southwestern Medical Center | 2019-07-23 |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (NCT03916627) | Regeneron Pharmaceuticals | 2019-07-23 |
| Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN (NCT03878979) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-07-08 |
| Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (NCT03838601) | University Health Network, Toronto | 2019-07-02 |
| Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma (NCT04490564) | Pharmassist Ltd | 2019-06-25 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT03650764) | Washington University School of Medicine | 2019-05-29 |
| Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy (NCT03655444) | Washington University School of Medicine | 2019-05-29 |
| SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma (NCT03874741) | Sinocelltech Ltd. | 2019-05-21 |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade (NCT03474497) | Megan Daly, MD | 2019-05-20 |
| Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma (NCT03817307) | Radboud University Medical Center | 2019-05-20 |
| Vaccination With Flt3L, Radiation, and Poly-ICLC (NCT03789097) | Icahn School of Medicine at Mount Sinai | 2019-04-05 |
| Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer (NCT04001543) | Institut du Cancer de Montpellier - Val d'Aurelle | 2019-03-14 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (NCT04139057) | Xinqiao Hospital of Chongqing | 2019-03-01 |
| A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients (NCT03602911) | West Virginia University | 2019-02-01 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma (NCT03896412) | Centre Henri Becquerel | 2019-01-21 |
| Study of NEO-201 in Solid Tumors Expansion Cohorts (NCT03476681) | Precision Biologics, Inc | 2019-01-18 |
| SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma (NCT03744208) | Shi Yuankai | 2018-12-30 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas (NCT03396718) | Technische Universität Dresden | 2018-11-29 |
| Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma (NCT03618654) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-11-01 |
| Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients (NCT03720158) | Coordinación de Investigación en Salud, Mexico | 2018-10-10 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors (NCT03665285) | NextCure, Inc. | 2018-10-01 |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (NCT03666273) | Bayer | 2018-09-12 |
| HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer (NCT03578406) | Xinqiao Hospital of Chongqing | 2018-09-01 |
| Phase Ib of L-NMMA and Pembrolizumab (NCT03236935) | The Methodist Hospital Research Institute | 2018-08-27 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (NCT03552718) | NantBioScience, Inc. | 2018-08-10 |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma (NCT03336606) | Providence Health & Services | 2018-07-25 |
| Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (NCT02999646) | Maxivax SA | 2018-07-25 |
| Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT03386357) | University of Erlangen-Nürnberg Medical School | 2018-07-20 |
| Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas (NCT03283605) | Centre hospitalier de l'Université de Montréal (CHUM) | 2018-07-17 |
| Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (NCT03412058) | UNICANCER | 2018-06-27 |
| Ruxolitinib in Operable Head and Neck Cancer (NCT03153982) | University of California, San Francisco | 2018-06-08 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
| Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT03498378) | Kathryn Gold | 2018-06-06 |
| BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer (NCT02706691) | University of Chicago | 2018-06-01 |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (NCT03526835) | Merus B.V. | 2018-05-02 |
| Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (NCT03524326) | Memorial Sloan Kettering Cancer Center | 2018-04-30 |
| Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma (NCT03389477) | Washington University School of Medicine | 2018-04-27 |
| Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC (NCT03450967) | Samsung Medical Center | 2018-04-11 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT03258554) | National Cancer Institute (NCI) | 2018-04-03 |
| Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (NCT03463161) | University of Chicago | 2018-03-23 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (NCT03435640) | Nektar Therapeutics | 2018-03-15 |
| Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer (NCT03383094) | Loren Mell, MD | 2018-03-15 |
| Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma (NCT03406247) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-02-12 |
| Building a Renewed ImaGe After Head & Neck Cancer Treatment (NCT03518671) | Medical University of South Carolina | 2018-02-08 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma (NCT03519048) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-01-17 |
| Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NCT03247712) | Providence Health & Services | 2018-01-15 |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (NCT03370276) | H. Lee Moffitt Cancer Center and Research Institute | 2017-12-20 |
| Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate (NCT03134846) | University Medical Center Groningen | 2017-12-16 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
| A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NCT03267121) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2017-10-01 |
| A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). (NCT03022409) | AstraZeneca | 2017-09-18 |
| REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (NCT03317327) | Oslo University Hospital | 2017-09-09 |
| Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. (NCT03196843) | The First Affiliated Hospital of Dalian Medical University | 2017-09-01 |
| Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer (NCT03281499) | University Health Network, Toronto | 2017-08-15 |
| A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (NCT03424291) | Henan Cancer Hospital | 2017-07-05 |
| An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer. (NCT03998696) | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 2017-07-01 |
| Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva (NCT05122507) | Technical University of Munich | 2017-05-08 |
| Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer (NCT03182959) | University of Arizona | 2017-04-24 |
| Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT02567422) | National Cancer Institute (NCI) | 2017-04-17 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (NCT03082534) | University of California, San Diego | 2017-03-28 |
| Anti-tumor Specific Immune Response in Head and Neck Cancers (NCT02881918) | Central Hospital, Nancy, France | 2017-03-14 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (NCT03049618) | University of Southern California | 2017-03-10 |
| Cell-free Tumor DNA in Head and Neck Cancer Patients (NCT03942380) | Christian von Buchwald | 2017-02-01 |
| AVID100 in Advanced Epithelial Carcinomas (NCT03094169) | Formation Biologics | 2017-02-01 |
| Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma (NCT02949700) | Baylor College of Medicine | 2017-01-26 |
| GlucoCEST MRI in Oncology (NCT03212157) | University College, London | 2017-01-06 |
| Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer (NCT02593929) | University of Pittsburgh | 2017-01-01 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers (NCT02643303) | Ludwig Institute for Cancer Research | 2016-12-28 |
| A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (NCT03096184) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2016-12-23 |
| Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer (NCT02794675) | Case Comprehensive Cancer Center | 2016-12-21 |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery (NCT02734537) | ECOG-ACRIN Cancer Research Group | 2016-11-23 |
| A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer (NCT02901483) | PharmaEngine | 2016-10-11 |
| Pembrolizumab in HNSCC With Residual Disease After Radiation (NCT02892201) | Yale University | 2016-09-08 |
| DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. (NCT02661152) | Danish Head and Neck Cancer Group | 2016-09-01 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer (NCT02777385) | Dan Zandberg | 2016-05-31 |
| PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC (NCT02544880) | Donald T. Weed, MD, FACS | 2016-04-25 |
| Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps (NCT03340038) | University of California, Davis | 2016-04-10 |